Clinical Trial Update: Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants [Phase 3]

View source ↗

Summary

A Phase 3 trial assessing immunogenicity and safety of GSK Infanrix Hexa given at 2, 4, and 6 months in healthy infants; study completed with results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acellular Pertussis Disease
• Diphtheria
• Haemophilus Influenzae Type Disease
• Hepatitis B
• Poliomyelitis
• Tetanus

Drugs mentioned

• Infanrix Hexa (DTPa-HBV-IPV/Hib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Poliomyelitis, Diphtheria | Phase 3 | Status: COMPLETED | Results posted: 2018-08-01